Premier Research Launches Oracle(R) Remote Data Capture Onsite 4.5.3
PHILADELPHIA, PA-July 7
-Premier Research Group Limited, the international clinical research services company, announced that it has implemented OraclexAE; Remote Data Capture Onsite 4.5.3, the enhanced version of Oracle's EDC application featuring new functionality to meet the needs of trial sponsors as well as investigative site personnel.
Premier Research has a long tradition of Oracle Clinical data management as an early adopter of the platform having first licensed it in 1997. Our global data operation team of more than 245 professionals has managed more than 350 studies using Oracle Clinical including 180 EDC studies.
The system's zero footprint deployment allows sites to rely solely on a web browser without loading or maintaining additional software streamlining system and site management. Electronic case report form (eCRF) pages, developed in HTML, open in two to three seconds. The system requires fewer key strokes to navigate pages, displays all information (captured data, discrepancy and audit information) on a single CRF screen, and allows multiple pages to be opened simultaneously. In addition, the re-architected patient data report offers significant performance gains and is better tailored for use in electronic submissions.
"Oracle RDC Onsite 4.5.3 provides us with powerful new functionality increasing the productivity and efficiency of investigative sites that will result in faster, more accurate data entry and accelerate the clinical trial process for our clients," said Walt Wunder, Executive Director, Global Data Operations for Premier Research.
About Premier Research
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for analgesia, CNS, oncology, and infectious disease and have a wealth of experience in medical device and pediatric research.
Premier Research has 32 offices and operates in more than 30 countries across North America and Europe employing more than 1,200 clinical professionals dedicated first and foremost to fulfilling each client's requirements in a timely, accurate, and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at our well-established network of dedicated clinical sites.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
